293 related articles for article (PubMed ID: 23690170)
1. Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
[TBL] [Abstract][Full Text] [Related]
2. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
3. The 'SPARC' of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review).
Rossi MK; Gnanamony M; Gondi CS
Int J Oncol; 2016 May; 48(5):1765-71. PubMed ID: 26983777
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma.
Damhofer H; Medema JP; Veenstra VL; Badea L; Popescu I; Roelink H; Bijlsma MF
Mol Oncol; 2013 Dec; 7(6):1031-42. PubMed ID: 23998958
[TBL] [Abstract][Full Text] [Related]
5. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
[TBL] [Abstract][Full Text] [Related]
6. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
[TBL] [Abstract][Full Text] [Related]
7. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
[TBL] [Abstract][Full Text] [Related]
8. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Cell Mol Life Sci; 2018 Mar; 75(6):1001-1012. PubMed ID: 28993833
[TBL] [Abstract][Full Text] [Related]
9. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
[TBL] [Abstract][Full Text] [Related]
10. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.
Ramu I; Buchholz SM; Patzak MS; Goetze RG; Singh SK; Richards FM; Jodrell DI; Sipos B; Ströbel P; Ellenrieder V; Hessmann E; Neesse A
EBioMedicine; 2019 Oct; 48():161-168. PubMed ID: 31597597
[TBL] [Abstract][Full Text] [Related]
11. Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer.
Munasinghe A; Malik K; Mohamedi F; Moaraf S; Kocher H; Jones L; Hill NJ
Cancer Lett; 2020 May; 477():88-96. PubMed ID: 32113990
[TBL] [Abstract][Full Text] [Related]
12. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Shintakuya R; Kondo N; Murakami Y; Uemura K; Nakagawa N; Okano K; Takahashi S; Sueda T
Pancreatology; 2018 Mar; 18(2):191-197. PubMed ID: 29295776
[TBL] [Abstract][Full Text] [Related]
13. SPARC expression in desmoplastic and non desmoplastic pancreatic carcinoma and cholangiocarcinoma.
Khetan K; Baloda V; Sahoo RK; Vishnubhathla S; Yadav R; Saraya A; Sharma A; Gupta SD; Das P
Pathol Res Pract; 2019 Dec; 215(12):152685. PubMed ID: 31727501
[TBL] [Abstract][Full Text] [Related]
14. [Nab-paclitaxel].
Lopez-Trabada Ataz D; Dumont S; André T
Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
[TBL] [Abstract][Full Text] [Related]
15. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients.
Miyoshi K; Sato N; Ohuchida K; Mizumoto K; Tanaka M
Anticancer Res; 2010 Mar; 30(3):867-71. PubMed ID: 20393008
[TBL] [Abstract][Full Text] [Related]
16. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
[TBL] [Abstract][Full Text] [Related]
17. Stromal depletion goes on trial in pancreatic cancer.
Garber K
J Natl Cancer Inst; 2010 Apr; 102(7):448-50. PubMed ID: 20339135
[No Abstract] [Full Text] [Related]
18. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer.
Brown TJ; Shaw PA; Karp X; Huynh MH; Begley H; Ringuette MJ
Gynecol Oncol; 1999 Oct; 75(1):25-33. PubMed ID: 10502421
[TBL] [Abstract][Full Text] [Related]
19. The role of SPARC expression in pancreatic cancer progression and patient survival.
Gundewar C; Sasor A; Hilmersson KS; Andersson R; Ansari D
Scand J Gastroenterol; 2015; 50(9):1170-4. PubMed ID: 25765175
[TBL] [Abstract][Full Text] [Related]
20. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]